Print this page
colorectal
-
Optimizing Colorectal Cancer Screening Among Patients with Diabetes in Safety-Net Primary Care Settings: Targeting Implementation Approaches.
Protocol: 002056Applicable Disease Sites: Colon
-
Video Education with Result Dependent dIsclosure (VERDI)
Protocol: 042207Principal Investigator:
- Deborah L Toppmeyer
Applicable Disease Sites: Breast
Colon
Kidney
Melanoma, Skin
Ovary
Pancreas
Prostate
Soft Tissue -
A First-in-Human Study of Mutant-Selective PI3K Alpha Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination with Fulvestrant in Patients with Advanced Breast Cancer.
Protocol: 042402Principal Investigator:
- Mridula A George
Applicable Disease Sites: Breast -
A Phase I, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-Tumor Activity of RO7589831 in Participants With Advanced Solid Tumors Harboring Microsatellite Instability (MSI) and/or Deficient Mismatch Repair (dMMR).
Protocol: 052407Principal Investigator:
- Sanjay Goel
Applicable Disease Sites: Any Site -
A Phase 2, Open-Label, Multicenter, Tumor-agnostic Study of MK-1084 as Monotherapy and in combination with Cetuximab, in Participants with KRAS G12C-Mutant, Advanced Solid Tumors.
Protocol: 052508Principal Investigator:
- Sanjay Goel
Applicable Disease Sites: Any Site -
PERitoneal Carcinomatosis LEveraging ctDNA guided treatment Study in GI Cancer (PERICLES Study).
Protocol: 072013Principal Investigator:
- Henry Richard Alexander
Applicable Disease Sites: Colon
Esophagus
Ill-Defined Sites
Other Digestive Organ
Pancreas
Rectum
Small Intestine
Stomach
Unknown Sites -
Preoperative ChemoRadiation and FOLFOXIRI To Escalate Complete Response for Rectal Cancer.
Protocol: 072202Principal Investigator:
- Salma Jabbour
Applicable Disease Sites: Rectum -
Colon Adjuvant Chemotherapy Based On Evaluation of Residual Disease.
Protocol: 072207Principal Investigator:
- Howard Hochster
Applicable Disease Sites: Colon -
Sequential Combined TAS-102 and Oxaliplatin Alternating with TAS-102 and Irinotecan (Sequential TASOXIRI) with Bevacizumab for Late-Line Metastatic Colorectal Cancer.
Protocol: 072303Principal Investigator:
- Howard Hochster
Applicable Disease Sites: Colon -
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer.
Protocol: 072405Principal Investigator:
- Patrick Boland
Applicable Disease Sites: Colon -
A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients with Refractory Advanced/Metastatic Microsatellite Stable Colorectal Cancer.
Protocol: 072503Principal Investigator:
- Howard Hochster
Applicable Disease Sites: Colon -
A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with FOLFOX versus Bevacizumab in Combination with FOLFOX for the First-line Treatment of Metastatic Colorectal Cancer.
Protocol: 072511Principal Investigator:
- Patrick Boland
Applicable Disease Sites: Colon -
Personalized Oncology Promoting Equity for Black Lives (PROPEL).
Protocol: 132309Principal Investigator:
- Anita Y Kinney
Applicable Disease Sites: Breast
Colon
Corpus Uteri
Ovary
Pancreas
Prostate -
Tracking Health and Resilience in Metastatic Colorectal Cancer: THRIVE-MCRC
Protocol: 132314Principal Investigator:
- Lisa Paddock
Applicable Disease Sites: Colon -
Biopsychosocial Study to Track Health and Responses to Living with Cancer in New Jersey (BioTHRIVE-NJ)
Protocol: 132416Principal Investigator:
- Lisa Paddock
Applicable Disease Sites: Colon
Rectum -
Translating Innovations in Cancer Screening into Substance Use Disorder
Care Settings (Just in Time)
Protocol: 132602Principal Investigator:
- Ana Tergas
Applicable Disease Sites: Cervix
Colon
- 1
- 2